Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0.44	0.44	1.92	18.05	5.4	6.7
Revenue Growth (YoY)	-45.35%	-77.08%	-89.34%	234.40%	-19.42%	-0.76%
Cost of Revenue	28.6	15.28	9.95	25.99	50.12	25.24
Gross Profit	-28.16	-14.84	-8.02	-7.94	-44.72	-18.54
Selling, General & Admin	20.31	17.24	10.3	13.91	24.66	19.76
Research & Development	11.68	8.8	5.12	8.05	11.21	7.26
Amortization of Goodwill & Intangibles	-	-	-	0.04	1.55	1.74
Operating Expenses	31.99	26.04	15.42	22	37.41	28.76
Operating Income	-60.16	-40.87	-23.44	-29.94	-82.13	-47.29
Interest Expense	-	-	-3.42	-4.17	-2.39	-
Interest & Investment Income	4.43	3.32	-	-	-	0.05
Other Non Operating Income (Expenses)	9.64	30.18	-0.76	-0.02	-0.02	0.41
EBT Excluding Unusual Items	-46.09	-7.37	-27.62	-34.13	-84.55	-46.84
Merger & Restructuring Charges	-	-	-	-7.5	-	-
Impairment of Goodwill	-	-	-3.91	-	-	-
Gain (Loss) on Sale of Investments	-	-	-	-	-	5.21
Pretax Income	-46.09	-35.02	-31.53	-41.63	-84.55	-67.18
Income Tax Expense	0.12	0.11	0.01	0.03	-0.2	-2.79
Earnings From Continuing Operations	-46.22	-35.13	-31.54	-41.66	-84.35	-64.38
Earnings From Discontinued Operations	-	-	-	-	-0.03	0.88
Net Income	-46.22	-35.13	-31.54	-41.66	-84.38	-63.5
Net Income to Common	-46.22	-35.13	-31.54	-41.66	-84.38	-63.5
Shares Outstanding (Basic)	9	4	0	0	0	0
Shares Outstanding (Diluted)	9	7	0	0	0	0
Shares Change (YoY)	1182.48%	2599.19%	608.45%	8.32%	41.86%	28.52%
EPS (Basic)	-4.98	-7.94	-113.58	-1062.65	-2331.41	-2489.12
EPS (Diluted)	-6.01	-20.91	-113.58	-1062.65	-2331.41	-2489.12
Free Cash Flow	-47.42	-49.06	-30.84	-26.85	-71.01	-40.6
Free Cash Flow Per Share	-5.11	-6.54	-111.04	-684.81	-1961.95	-1591.55
Gross Margin	-	-	-	-43.98%	-	-276.70%
Operating Margin	-13640.59%	-9267.80%	-1218.50%	-165.86%	-1521.56%	-705.99%
Profit Margin	-10479.82%	-7965.76%	-1639.50%	-230.78%	-1563.10%	-947.90%
Free Cash Flow Margin	-10752.38%	-11123.81%	-1602.81%	-148.72%	-1315.39%	-606.09%
EBITDA	-59.78	-40.7	-23.29	-29.77	-80.48	-45.45
EBITDA Margin	-	-	-	-164.94%	-	-
D&A For EBITDA	0.37	0.17	0.16	0.17	1.66	1.84
EBIT	-60.16	-40.87	-23.44	-29.94	-82.13	-47.29
EBIT Margin	-	-	-	-165.86%	-	-
Revenue as Reported	0.44	0.44	1.92	18.05	5.4	6.7

Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q